Clinical trial results:
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab plus Docetaxel versus Placebo plus Docetaxel in Patients with Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or after Platinum-Based Therapy.

Summary

EudraCT number	2014-003655-66
Trial protocol	ES HU DK DE NL PL GB BE GR IT
Global end of trial date	26 July 2022

Results information

Result version number	v1 (current)
This version publication date	09 August 2023
First version publication date	09 August 2023

Trial information

Trial identification

Sponsor protocol code	I4T-MC-JVDC

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02426125
WHO universal trial number (UTN)	-
Other trial identifiers	Trial Number: 15679

Notes:

Sponsors

Sponsor organisation name	Eli Lilly and Company
Sponsor organisation address	Lilly Corporate Center, Indianapolis, IN, United States, 46285
Public contact	Available Mon Fri 9 AM 5 PM EST, Eli Lilly and Company, 1 877CTLilly,
Scientific contact	Available Mon Fri 9 AM 5 PM EST, Eli Lilly and Company, 1 8772854559,

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	26 July 2022
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	26 July 2022
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The main purpose of this study is to evaluate the safety and efficacy of the study drug ramucirumab in combination with docetaxel in participants with urothelial cancer who failed prior platinum-based therapy.

Protection of trial subjects:

This study was conducted in accordance with International Conference on Harmonization (ICH) Good Clinical Practice, and the principles of the Declaration of Helsinki, in addition to following the laws and regulations of the country or countries in which a study is conducted.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	13 July 2015
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Romania: 10
Country: Number of subjects enrolled	Hungary: 13
Country: Number of subjects enrolled	United States: 35
Country: Number of subjects enrolled	Japan: 54
Country: Number of subjects enrolled	Ukraine: 8
Country: Number of subjects enrolled	United Kingdom: 42
Country: Number of subjects enrolled	Russian Federation: 30
Country: Number of subjects enrolled	Spain: 37
Country: Number of subjects enrolled	Greece: 26
Country: Number of subjects enrolled	Canada: 9
Country: Number of subjects enrolled	Korea, Republic of: 25
Country: Number of subjects enrolled	Netherlands: 35
Country: Number of subjects enrolled	Turkey: 28
Country: Number of subjects enrolled	Belgium: 7
Country: Number of subjects enrolled	Taiwan: 31
Country: Number of subjects enrolled	Denmark: 11
Country: Number of subjects enrolled	Poland: 8
Country: Number of subjects enrolled	Italy: 37
Country: Number of subjects enrolled	Mexico: 4

Country: Number of subjects enrolled	Israel: 18
Country: Number of subjects enrolled	Australia: 12
Country: Number of subjects enrolled	France: 34
Country: Number of subjects enrolled	Germany: 16
Worldwide total number of subjects	530
EEA total number of subjects	234

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	239
From 65 to 84 years	289
85 years and over	2

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

Completers include participants who are confirmed to be alive at study completion.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	Yes
Arm title	Ramucirumab + Docetaxel

Arm description:

Ramucirumab (10 milligram/kilogram [mg/kg]) intravenously (IV) plus docetaxel (75 milligram/square meter [mg/m²]) IV on day 1 of each 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.

Arm type	Experimental
Investigational medicinal product name	Ramucirumab
Investigational medicinal product code	
Other name	LY3009806
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Participants received 10 mg/kg of Ramucirumab intravenously (IV) on day 1 of each 21-day cycle.

Investigational medicinal product name	Docetaxel
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Participants received 75 mg/m² of docetaxel Intravenously on day 1 of each 21-day cycle.

Arm title	Placebo + Docetaxel

Arm description:

Placebo IV plus docetaxel (75 mg/m²) IV on day 1 of each 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.

Arm type	Placebo
Investigational medicinal product name	Docetaxel
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Participants received 75 mg/m² of docetaxel intravenously on day 1 of each 21-day cycle.

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Participants received matching placebo intravenously on day 1 of each 21-day cycle.

Number of subjects in period 1	Ramucirumab + Docetaxel	Placebo + Docetaxel
Started	263	267
Received at least one dose of study drug	258	265
Completed	46	39
Not completed	217	228
Adverse event, serious fatal	185	200
Consent withdrawn by subject	13	14
Randomized, But Never Treated	5	2
Lost to follow-up	14	12

Baseline characteristics

Reporting groups	
Reporting group title	Ramucirumab + Docetaxel
Reporting group description:	
Ramucirumab (10 milligram/kilogram [mg/kg]) intravenously (IV) plus docetaxel (75 milligram/square meter [mg/m²]) IV on day 1 of each 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.	
Reporting group title	Placebo + Docetaxel
Reporting group description:	
Placebo IV plus docetaxel (75 mg/m²) IV on day 1 of each 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.	

Reporting group values	Ramucirumab + Docetaxel	Placebo + Docetaxel	Total
Number of subjects	263	267	530
Age categorical Units: Subjects			
Age continuous Units: years			
arithmetic mean	64.6	64.8	
standard deviation	± 9.9	± 9.2	-
Gender categorical Units: Subjects			
Female	50	52	102
Male	213	215	428
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino	13	10	23
Not Hispanic or Latino	208	219	427
Unknown or Not Reported	42	38	80
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	1	0	1
Asian	54	61	115
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	3	2	5
White	203	204	407
More than one race	0	0	0
Unknown or Not Reported	2	0	2
Region of Enrollment Units: Subjects			
Romania	5	5	10
Hungary	5	8	13
United States	17	18	35
Japan	24	30	54
Ukraine	5	3	8
United Kingdom	18	24	42

Russia	18	12	30
Spain	22	15	37
Greece	13	13	26
Canada	4	5	9
South Korea	16	9	25
Netherlands	17	18	35
Turkey	11	17	28
Belgium	6	1	7
Taiwan	13	18	31
Denmark	5	6	11
Poland	4	4	8
Italy	23	14	37
Mexico	3	1	4
Israel	7	11	18
Australia	6	6	12
France	16	18	34
Germany	5	11	16

End points

End points reporting groups

Reporting group title	Ramucirumab + Docetaxel
Reporting group description:	
Ramucirumab (10 milligram/kilogram [mg/kg]) intravenously (IV) plus docetaxel (75 milligram/square meter [mg/m²]) IV on day 1 of each 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.	
Reporting group title	Placebo + Docetaxel
Reporting group description:	
Placebo IV plus docetaxel (75 mg/m²) IV on day 1 of each 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.	

Primary: Progression Free Survival (PFS)

End point title	Progression Free Survival (PFS)
End point description:	
PFS defined as time from first day of therapy to first evidence of disease progression defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1) or death from any cause. Progressive Disease (PD) is at least 20% increase in sum of diameters of target lesions, with reference being the smallest sum on study and plus absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If participant does not have complete baseline disease assessment, then PFS time was censored at date of first dose, regardless of whether or not objectively determined disease progression or death has been observed for participant. If participant is not known to have died or have objective progression as of data inclusion cutoff date for analysis, PFS time was censored at last adequate tumor assessment date. Analysis population description (APD): All randomized participants. Censored participants: Ramucirumab + Docetaxel = 51, Placebo + Docetaxel =31.	
End point type	Primary
End point timeframe:	
Randomization to Radiological Disease Progression or Death from Any Cause (Up to 29.7 Months)	

End point values	Ramucirumab + Docetaxel	Placebo + Docetaxel		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	263	267		
Units: Months				
median (confidence interval 95%)	4.07 (3.29 to 4.83)	2.76 (2.60 to 2.89)		

Statistical analyses

Statistical analysis title	Progression Free Survival (PFS)
Comparison groups	Ramucirumab + Docetaxel v Placebo + Docetaxel

Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0002 [1]
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.696
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.573
upper limit	0.845

Notes:

[1] - Stratified

Secondary: Overall Survival (OS)

End point title	Overall Survival (OS)

End point description:

OS is the time from the date of randomization to the date of death from any cause. For each participant who is not known to have died as of the data inclusion cutoff date for a particular analysis, OS was censored for that analysis at the last known alive date prior to the data inclusion cutoff date. APD: All randomized participants. Censored participants: Ramucirumab + Docetaxel = 78, Placebo + Docetaxel = 67.

End point type	Secondary

End point timeframe:

Randomization to Date of Death from Any Cause (Up to 31.1 Months)

End point values	Ramucirumab + Docetaxel	Placebo + Docetaxel		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	263	267		
Units: Months				
median (confidence interval 95%)	9.40 (7.89 to 11.43)	7.85 (7.00 to 9.30)		

Statistical analyses

Statistical analysis title	Overall Survival (OS)
Comparison groups	Ramucirumab + Docetaxel v Placebo + Docetaxel
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2461 [2]
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.887

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.724
upper limit	1.086

Notes:

[2] - Stratified

Secondary: Percentage of Participants with an Objective Response Rate (ORR)

End point title	Percentage of Participants with an Objective Response Rate (ORR)

End point description:

ORR is defined as the percentage of participants who achieve a best overall response of complete response (CR) + partial response (PR). ORR = CR + PR. CR is defined as disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to < 10 millimeter (mm). Tumor-marker results must have normalized. PR is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Best overall response is classified based on the overall responses assessed by study investigators according to RECIST v1.1. APD: All randomized participants.

End point type	Secondary

End point timeframe:

Randomization to Disease Progression (Up to 29.7 Months)

End point values	Ramucirumab + Docetaxel	Placebo + Docetaxel		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	263	267		
Units: percentage of participants				
number (confidence interval 95%)	25.9 (20.6 to 31.1)	13.9 (9.7 to 18.0)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants with Disease Control Rate (DCR)

End point title	Percentage of Participants with Disease Control Rate (DCR)

End point description:

DCR is percentage of participants with a best overall response of CR, PR, or Stable Disease (SD) as per Response using RECIST v1.1. Target lesions - CR: Disappearance of all lesions; any pathological lymph nodes must have reduction in short axis to <10 mm. PR: At least a 30% decrease in sum of diameters of lesions vs baseline sum. Progressive Disease (PD): At least a 20% increase in sum of diameters of lesions vs smallest sum on study (the sum must also demonstrate an absolute increase of at least 5 mm); or the appearance of new lesion(s). SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Non target lesions - CR: Disappearance of all lesions and normalization of tumor marker levels; all lymph nodes must be non-pathological in size. Non-CR/Non-PD: Persistence of lesion(s) and/or maintenance of abnormal tumor marker levels. PD: Unequivocal progression of existing lesions or the appearance of new lesion(s). APD: All randomized participants.

End point type	Secondary

End point timeframe:

Randomization to Disease Progression (Up to 29.7 Months)

End point values	Ramucirumab + Docetaxel	Placebo + Docetaxel		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	263	267		
Units: percentage of participants				
number (confidence interval 95%)	65.4 (59.7 to 71.1)	55.1 (49.1 to 61.0)		

Statistical analyses

No statistical analyses for this end point

Secondary: Duration of Response (DoR)

End point title	Duration of Response (DoR)

End point description:

Objective response was achieved if they had a best overall response of CR or PR. Target lesions- CR: Disappearance of all lesions;any pathological lymph nodes have reduction in short axis to <10 mm.PR: At least a 30% decrease in sum of diameters of lesions vs the baseline sum.PD: At least a 20% increase in sum of diameters of lesions vs smallest sum on study(the sum must also demonstrate an absolute increase of at least 5 mm); or appearance of new lesion(s). Non target lesions - CR: Disappearance of all lesions and normalization of tumour marker levels; all lymph nodes must be non-pathological in size. Non-CR/Non-PD: Persistence of lesion(s) and/or maintenance of abnormal tumor marker levels. PD: Unequivocal progression of existing lesions or appearance of new lesion(s). If a participant was not known to have died or have radiographically documented PD as of data inclusion cutoff date, DOR was censored at the date of the last adequate tumor assessment. APD: All randomized participants

End point type	Secondary

End point timeframe:

Date of Complete Response (CR) or Partial Response (PR) to Date of Objective Disease Progression or Death Due to Any Cause (Up to 28.4 Months)
Participants censored in Ramucirumab + Docetaxel = 12 and in Placebo + Docetaxel = 5.

End point values	Ramucirumab + Docetaxel	Placebo + Docetaxel		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	68	37		
Units: Months				
median (confidence interval 95%)	5.32 (3.94 to 6.87)	4.17 (3.29 to 5.55)		

Statistical analyses

Statistical analysis title	Duration of Response (DoR)
Comparison groups	Ramucirumab + Docetaxel v Placebo + Docetaxel

Number of subjects included in analysis	105
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.189
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.74
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.473
upper limit	1.158

Secondary: Time to Deterioration in Quality of Life (QoL) on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) - Global Health Status/ QoL Scale

End point title	Time to Deterioration in Quality of Life (QoL) on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) - Global Health Status/ QoL Scale

End point description:

Time to sustained deterioration was defined as time from randomization to first worsening in QoL with no subsequent non-worsened assessment. Worsening in global health status/QoL was defined as a decrease of ≥10 points on a 100-point scale. If a participant did not report worsening, time to sustained deterioration was censored at date of last non-worsened assessment. Scores for global health status/QoL range from 0 to 100 with; higher scores representing better QoL. APD: All randomized participants. Censored participants: Ramucirumab + Docetaxel = 160, Placebo + Docetaxel = 173.

End point type	Secondary

End point timeframe:

Randomization, 30 Days After Treatment Discontinuation (Up to 18 Months)

End point values	Ramucirumab + Docetaxel	Placebo + Docetaxel		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	263	267		
Units: Months				
median (confidence interval 95%)	6.87 (4.24 to 8.90)	4.60 (3.52 to 5.55)		

Statistical analyses

Statistical analysis title	Global health status/QoL
Comparison groups	Ramucirumab + Docetaxel v Placebo + Docetaxel

Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority[3]
P-value	= 0.357 [4]
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.879
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.663
upper limit	1.167

Notes:

[3] - Global health status/QoL

[4] - Stratified

Secondary: Change from Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score

End point title	Change from Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score

End point description:

The EQ-5D-5L is a standardized instrument for use as a measure of self-reported health status. Participants completed the 5-level (no problem, slight problem, moderate problem, severe problem, and inability or extreme problem), 5-dimension (mobility, self-care,
usual activities, pain/discomfort, and anxiety/depression) questionnaire concerning their current health state. A unique EQ-5D health state is defined by combining 1 level from each of the 5 dimensions. Scores range from 0 (death) to 1 (perfect health), but scores <0 are possible based on the algorithm.
APD: All randomized participants with baseline and 30-day follow-up data.

End point type	Secondary

End point timeframe:

Randomization, 30 Days After Treatment Discontinuation (Up to 18 Months)

End point values	Ramucirumab + Docetaxel	Placebo + Docetaxel		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	83	102		
Units: units on a scale				
arithmetic mean (standard deviation)	-0.10 (± 0.26)	-0.19 (± 0.26)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Visual Analogue Scale (VAS)

End point title	Change from Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Visual Analogue Scale (VAS)

End point description:

The EQ-5D-5L is a standardized instrument for use as a measure of self-reported health status. A unique

EQ-5D health state is defined by combining 1 level from each of the 5 dimensions. Participants indicated their current health status by marking on a VAS ranging from 100 (best imaginable health state) to 0 (worst imaginable health state).
APD: All randomized participants with baseline and 30-day follow-up data.

End point type	Secondary

End point timeframe:

Randomization, 30 Days After Treatment Discontinuation (Up to 18 Months)

End point values	Ramucirumab + Docetaxel	Placebo + Docetaxel		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	86	105		
Units: millimeter (mm)				
arithmetic mean (standard deviation)	-7.87 (± 17.95)	-10.91 (± 16.77)		

Statistical analyses

No statistical analyses for this end point

Secondary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Ramucirumab

End point title	Pharmacokinetics (PK): Maximum Concentration (Cmax) of Ramucirumab[5]

End point description:

Cmax of Ramucirumab at the end of ramucirumab infusion. APD: All randomized participants who had evaluable PK data.

End point type	Secondary

End point timeframe:

Cycle 1 and Cycle 9, Day 1: Predose, Postdose

Notes:

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The endpoint is planned only for Ramucirumab arm in the baseline period per protocol.

End point values	Ramucirumab + Docetaxel			
Subject group type	Reporting group			
Number of subjects analysed	209[6]			
Units: microgram/milliliter (µg/mL)				
geometric mean (geometric coefficient of variation)				
Cycle 1	199 (± 28)			
Cycle 9	265 (± 29)			

Notes:

[6] - Cycle 1: 209
Cycle 9: 22

Statistical analyses

No statistical analyses for this end point

Secondary: PK: Minimum Concentration (Cmin) of Ramucirumab

End point title	PK: Minimum Concentration (Cmin) of Ramucirumab[7]

End point description:

Cmin of Ramucirumab following administration every 3 weeks. APD: All randomized participants who had evaluable PK data.

End point type	Secondary

End point timeframe:

Day 1 of Cycle 2, 3, 5 and 9 (Predose and Postdose)

Notes:

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The endpoint is planned only for Ramucirumab arm in the baseline period per protocol.

End point values	Ramucirumab + Docetaxel			
Subject group type	Reporting group			
Number of subjects analysed	188[8]			
Units: µg/mL				
geometric mean (geometric coefficient of variation)				
Cycle 2	14.9 (± 64)			
Cycle 3	23.5 (± 63)			
Cycle 5	32.5 (± 70)			
Cycle 9	48.9 (± 56)			

Notes:

[8] - Cycle 2: 188; Cycle 3: 146; Cycle 5: 94; Cycle 9: 25

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants with Anti-Ramucirumab Antibodies

End point title	Number of Participants with Anti-Ramucirumab Antibodies

End point description:

Number of participants with positive treatment emergent anti-ramucirumab antibodies was summarized by treatment group. APD: All randomized participants who received at least one dose of study drug at baseline and post-baseline.

End point type	Secondary

End point timeframe:

29.7 Months

End point values	Ramucirumab + Docetaxel	Placebo + Docetaxel		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	199	213		
Units: participants	3	8		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Up to 64.7 Months

Adverse event reporting additional description:

All randomized participants who received at least one dose of study drug. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	26.0

Reporting groups

Reporting group title	Placebo+Docetaxel

Reporting group description:

Placebo IV plus docetaxel (75 mg/m²) IV on day 1 of each 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.

Reporting group title	Ramucirumab + Docetaxel

Reporting group description:

Ramucirumab (10 mg/kg) IV plus docetaxel (75 mg/m²) IV on day 1 of each 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.

Serious adverse events	Placebo+Docetaxel	Ramucirumab + Docetaxel	
Total subjects affected by serious adverse events			
subjects affected / exposed	107 / 265 (40.38%)	111 / 258 (43.02%)	
number of deaths (all causes)	209	193	
number of deaths resulting from adverse events	5	8	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
tumour haemorrhage			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
arterial haemorrhage			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

aortic aneurysm				
alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)		
occurrences causally related to treatment / all	0 / 1	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
deep vein thrombosis				
alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	2 / 265 (0.75%)	2 / 258 (0.78%)		
occurrences causally related to treatment / all	0 / 2	1 / 2		
deaths causally related to treatment / all	0 / 0	0 / 0		
embolism				
alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)		
occurrences causally related to treatment / all	0 / 1	1 / 1		
deaths causally related to treatment / all	0 / 0	0 / 0		
haematoma				
alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)		
occurrences causally related to treatment / all	0 / 1	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
hypertension				
alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	0 / 265 (0.00%)	2 / 258 (0.78%)		
occurrences causally related to treatment / all	0 / 0	2 / 2		
deaths causally related to treatment / all	0 / 0	0 / 0		
hypotension				
alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)		
occurrences causally related to treatment / all	1 / 1	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
venous occlusion				
alternative dictionary used: MedDRA 26.0				

subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
asthenia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	1 / 1	0 / 0	
chest pain			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
death			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	2 / 258 (0.78%)	
occurrences causally related to treatment / all	1 / 2	1 / 2	
deaths causally related to treatment / all	1 / 2	1 / 2	
fatigue			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	5 / 258 (1.94%)	
occurrences causally related to treatment / all	2 / 2	3 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
general physical health deterioration			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
generalised oedema			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
malaise			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
mucosal inflammation			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
non-cardiac chest pain			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	2 / 258 (0.78%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
pain			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
pyrexia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	9 / 265 (3.40%)	3 / 258 (1.16%)	
occurrences causally related to treatment / all	2 / 10	2 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
sudden death			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	

Reproductive system and breast disorders			
female genital tract fistula			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed[1]	0 / 265 (0.00%)	1 / 49 (2.04%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
chronic obstructive pulmonary disease			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
dyspnoea			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	3 / 265 (1.13%)	3 / 258 (1.16%)	
occurrences causally related to treatment / all	1 / 3	3 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
epistaxis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
hiccups			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
laryngeal inflammation			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

obstructive airways disorder			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
pleural effusion			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	7 / 265 (2.64%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	1 / 8	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
pneumonitis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	2 / 258 (0.78%)	
occurrences causally related to treatment / all	1 / 1	1 / 2	
deaths causally related to treatment / all	1 / 1	0 / 1	
pneumothorax			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
pulmonary embolism			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	1 / 2	0 / 1	
deaths causally related to treatment / all	1 / 1	0 / 0	
pulmonary hypertension			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
delirium			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	2 / 265 (0.75%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
mental status changes			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Product issues			
device connection issue			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
blood creatinine increased			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
neutrophil count decreased			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	2 / 258 (0.78%)	
occurrences causally related to treatment / all	3 / 3	3 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
platelet count decreased			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	2 / 258 (0.78%)	
occurrences causally related to treatment / all	0 / 1	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
fall			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
infusion related reaction			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	2 / 258 (0.78%)	
occurrences causally related to treatment / all	1 / 1	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
lower limb fracture			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
urostomy complication			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
arteriospasm coronary			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
cardiac arrest			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	1 / 1	
cardiac failure			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
cardiac failure congestive			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
intracardiac thrombus			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
myocardial infarction			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	2 / 258 (0.78%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
pericardial effusion			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
supraventricular tachycardia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
basilar artery thrombosis			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	1 / 1	
cerebrovascular accident			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
cerebral ischaemia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
dizziness			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
headache			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
presyncope			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
subarachnoid haemorrhage			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

syncope			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
transient ischaemic attack			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
anaemia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	4 / 265 (1.51%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	1 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
blood loss anaemia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
febrile neutropenia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	13 / 265 (4.91%)	17 / 258 (6.59%)	
occurrences causally related to treatment / all	11 / 14	20 / 20	
deaths causally related to treatment / all	0 / 0	0 / 0	
leukopenia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	3 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
neutropenia			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	2 / 265 (0.75%)	4 / 258 (1.55%)	
occurrences causally related to treatment / all	2 / 2	5 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
pancytopenia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear and labyrinth disorders			
vertigo			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
abdominal pain			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 1	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
anal fistula			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ascites			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
constipation			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
colitis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
gastric haemorrhage			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	1 / 1	
diarrhoea			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	4 / 265 (1.51%)	6 / 258 (2.33%)	
occurrences causally related to treatment / all	3 / 5	5 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
fistula of small intestine			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
enterovesical fistula			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	1 / 1	
enterocolitis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

gastrointestinal haemorrhage			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	2 / 258 (0.78%)	
occurrences causally related to treatment / all	1 / 1	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
gastrointestinal ulcer			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
haemorrhoids			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ileal perforation			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
intestinal ischaemia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
intestinal obstruction			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	3 / 258 (1.16%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
intestinal perforation			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
large intestine perforation			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	2 / 258 (0.78%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
oesophagitis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
nausea			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	2 / 258 (0.78%)	
occurrences causally related to treatment / all	1 / 2	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
tooth disorder			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
rectal haemorrhage			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
small intestinal obstruction			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

small intestinal perforation			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
stomatitis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
upper gastrointestinal haemorrhage			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
vomiting			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	3 / 258 (1.16%)	
occurrences causally related to treatment / all	2 / 2	3 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
cholelithiasis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
dermatitis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
rash			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
acute kidney injury			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	3 / 258 (1.16%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 0	
haematuria			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	6 / 265 (2.26%)	4 / 258 (1.55%)	
occurrences causally related to treatment / all	1 / 6	1 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
hydronephrosis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
renal failure			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	3 / 258 (1.16%)	
occurrences causally related to treatment / all	0 / 0	1 / 3	
deaths causally related to treatment / all	0 / 0	1 / 2	
ureteric stenosis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
urinary tract obstruction			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	1 / 265 (0.38%)	2 / 258 (0.78%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocrine disorders			
adrenal insufficiency			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
back pain			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
bone pain			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
fistula			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
myalgia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
muscular weakness			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
abdominal abscess			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
appendicitis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
bronchitis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
bacteraemia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
cellulitis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
cystitis			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
clostridium difficile colitis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
diverticulitis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
device related infection			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	3 / 258 (1.16%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
gastroenteritis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
gingivitis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
kidney infection			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

lower respiratory tract infection			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
infection			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
neutropenic sepsis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	1 / 1	
pneumonia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	8 / 265 (3.02%)	5 / 258 (1.94%)	
occurrences causally related to treatment / all	3 / 8	3 / 5	
deaths causally related to treatment / all	1 / 3	0 / 0	
pneumonia aspiration			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
pyelonephritis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	2 / 258 (0.78%)	
occurrences causally related to treatment / all	1 / 2	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
respiratory tract infection			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
sepsis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	5 / 265 (1.89%)	7 / 258 (2.71%)	
occurrences causally related to treatment / all	5 / 5	3 / 7	
deaths causally related to treatment / all	0 / 0	1 / 4	
stoma site abscess			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
toxic shock syndrome			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
urosepsis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	5 / 265 (1.89%)	2 / 258 (0.78%)	
occurrences causally related to treatment / all	3 / 5	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
urinary tract infection			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	11 / 265 (4.15%)	10 / 258 (3.88%)	
occurrences causally related to treatment / all	2 / 15	2 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
dehydration			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
decreased appetite			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
diabetic metabolic decompensation			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
hyperglycaemia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
hyperkalaemia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	2 / 258 (0.78%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
hyponatraemia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	3 / 258 (1.16%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	

Notes:

[1] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
Justification: Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Placebo+Docetaxel	Ramucirumab + Docetaxel	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	251 / 265 (94.72%)	241 / 258 (93.41%)	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
neuroma			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
pyogenic granuloma			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
tumour necrosis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
tumour pain			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	9 / 265 (3.40%)	1 / 258 (0.39%)	
occurrences (all)	13	1	
Vascular disorders			
cyanosis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
deep vein thrombosis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	4 / 265 (1.51%)	2 / 258 (0.78%)	
occurrences (all)	4	2	
embolism			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	0 / 258 (0.00%)	
occurrences (all)	2	0	
flushing			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	2 / 265 (0.75%)	4 / 258 (1.55%)	
occurrences (all)	2	5	
haematoma			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
hot flush			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	2 / 258 (0.78%)	
occurrences (all)	2	2	
hyperaemia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
hypotension			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	8 / 265 (3.02%)	7 / 258 (2.71%)	
occurrences (all)	8	10	
hypertension			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	15 / 265 (5.66%)	34 / 258 (13.18%)	
occurrences (all)	22	66	
lymphocele			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences (all)	1	1	
lymphoedema			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	1 / 258 (0.39%)	
occurrences (all)	2	1	
pallor			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	

pelvic venous thrombosis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	2	0	
phlebitis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	2 / 258 (0.78%)	
occurrences (all)	0	3	
thrombosis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
venous thrombosis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
varicose vein			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
vasculitis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences (all)	1	6	
vena cava thrombosis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
venous occlusion			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
Surgical and medical procedures			

catheter placement			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
central venous catheterisation			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences (all)	1	1	
endodontic procedure			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
nail operation			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
paracentesis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
skin lesion removal			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
tooth extraction			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
General disorders and administration site conditions			
administration site extravasation			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
administration site rash			
alternative dictionary used:			

MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
asthenia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	24 / 265 (9.06%)	29 / 258 (11.24%)	
occurrences (all)	38	55	
catheter site erythema			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
chest discomfort			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	2 / 258 (0.78%)	
occurrences (all)	0	2	
chest pain			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	4 / 265 (1.51%)	1 / 258 (0.39%)	
occurrences (all)	4	1	
chills			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	9 / 265 (3.40%)	6 / 258 (2.33%)	
occurrences (all)	12	7	
face oedema			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	3 / 258 (1.16%)	
occurrences (all)	1	3	
extravasation			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	2	0	
fatigue			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	106 / 265 (40.00%)	98 / 258 (37.98%)	
occurrences (all)	188	186	
gait disturbance			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
generalised oedema			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	2	
general physical health deterioration			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	1 / 258 (0.39%)	
occurrences (all)	2	1	
hypothermia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
injection site reaction			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	5 / 258 (1.94%)	
occurrences (all)	1	12	
injection site extravasation			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
infusion site reaction			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	2	
infusion site extravasation			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	4 / 258 (1.55%)	
occurrences (all)	0	4	

influenza like illness			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	7 / 265 (2.64%)	14 / 258 (5.43%)	
occurrences (all)	7	15	
localised oedema			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	6 / 265 (2.26%)	1 / 258 (0.39%)	
occurrences (all)	6	2	
malaise			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	10 / 265 (3.77%)	18 / 258 (6.98%)	
occurrences (all)	16	31	
moaning			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
mucosal disorder			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	2	
mucosal inflammation			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	4 / 265 (1.51%)	13 / 258 (5.04%)	
occurrences (all)	7	26	
nodule			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
non-cardiac chest pain			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	4 / 265 (1.51%)	4 / 258 (1.55%)	
occurrences (all)	6	4	
oedema peripheral			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	34 / 265 (12.83%)	38 / 258 (14.73%)	
occurrences (all)	44	52	
pain			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	8 / 265 (3.02%)	10 / 258 (3.88%)	
occurrences (all)	8	14	
oedema			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	3 / 258 (1.16%)	
occurrences (all)	1	3	
peripheral swelling			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	2 / 258 (0.78%)	
occurrences (all)	0	3	
pyrexia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	42 / 265 (15.85%)	44 / 258 (17.05%)	
occurrences (all)	63	66	
swelling			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	2 / 258 (0.78%)	
occurrences (all)	1	2	
swelling face			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	2 / 258 (0.78%)	
occurrences (all)	1	2	
tenderness			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
thirst decreased			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	

Immune system disorders			
allergy to arthropod sting			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
drug hypersensitivity			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences (all)	1	2	
hypersensitivity			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	4 / 265 (1.51%)	2 / 258 (0.78%)	
occurrences (all)	5	2	
seasonal allergy			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences (all)	1	1	
Reproductive system and breast disorders			
breast pain			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
female genital tract fistula			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed[2]	0 / 265 (0.00%)	1 / 49 (2.04%)	
occurrences (all)	0	1	
genital haemorrhage			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	3	0	
genital ulceration			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
gynaecomastia			

alternative dictionary used: MedDRA 26.0			
subjects affected / exposed[3]	1 / 214 (0.47%)	1 / 209 (0.48%)	
occurrences (all)	1	1	
intermenstrual bleeding			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed[4]	0 / 265 (0.00%)	1 / 49 (2.04%)	
occurrences (all)	0	2	
oedema genital			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences (all)	1	1	
pelvic discomfort			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences (all)	1	1	
pelvic organ prolapse			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
pelvic pain			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	4 / 265 (1.51%)	5 / 258 (1.94%)	
occurrences (all)	4	5	
penile pain			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed[5]	1 / 214 (0.47%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
perineal pain			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
perineal ulceration			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
scrotal oedema			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed[6]	1 / 214 (0.47%)	3 / 209 (1.44%)	
occurrences (all)	1	3	
scrotal pain			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed[7]	0 / 265 (0.00%)	3 / 209 (1.44%)	
occurrences (all)	0	3	
scrotal swelling			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed[8]	1 / 214 (0.47%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
testicular oedema			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed[9]	1 / 214 (0.47%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
testicular pain			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed[10]	1 / 214 (0.47%)	1 / 209 (0.48%)	
occurrences (all)	1	1	
vaginal haemorrhage			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed[11]	1 / 51 (1.96%)	1 / 49 (2.04%)	
occurrences (all)	1	1	
vulvovaginal pruritus			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed[12]	0 / 265 (0.00%)	1 / 49 (2.04%)	
occurrences (all)	0	1	
vulval haemorrhage			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed[13]	0 / 265 (0.00%)	1 / 49 (2.04%)	
occurrences (all)	0	1	

Respiratory, thoracic and mediastinal disorders			
aphonia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
bronchospasm			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
chronic obstructive pulmonary disease			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
chylothorax			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
cough			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	26 / 265 (9.81%)	21 / 258 (8.14%)	
occurrences (all)	29	30	
dyspnoea			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	34 / 265 (12.83%)	32 / 258 (12.40%)	
occurrences (all)	40	50	
dysphonia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	3 / 265 (1.13%)	8 / 258 (3.10%)	
occurrences (all)	3	10	
dry throat			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
dyspnoea exertional			

alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	3 / 265 (1.13%)	1 / 258 (0.39%)	
occurrences (all)	3	1	
epistaxis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	14 / 265 (5.28%)	39 / 258 (15.12%)	
occurrences (all)	16	56	
haemoptysis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
hiccups			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	8 / 265 (3.02%)	14 / 258 (5.43%)	
occurrences (all)	8	21	
hypoxia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences (all)	1	1	
laryngeal inflammation			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
laryngeal pain			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
lung opacity			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
nasal dryness			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	1 / 265 (0.38%)	2 / 258 (0.78%)		
occurrences (all)	1	2		
oropharyngeal pain				
alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	5 / 265 (1.89%)	10 / 258 (3.88%)		
occurrences (all)	5	11		
pleural effusion				
alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	2 / 265 (0.75%)	4 / 258 (1.55%)		
occurrences (all)	2	4		
pneumonitis				
alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	2 / 265 (0.75%)	4 / 258 (1.55%)		
occurrences (all)	2	4		
productive cough				
alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	2 / 265 (0.75%)	4 / 258 (1.55%)		
occurrences (all)	2	5		
pulmonary embolism				
alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	2 / 265 (0.75%)	2 / 258 (0.78%)		
occurrences (all)	2	2		
pulmonary fibrosis				
alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)		
occurrences (all)	0	1		
pulmonary haemorrhage				
alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)		
occurrences (all)	1	0		
rhinorrhoea				
alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	6 / 265 (2.26%)	7 / 258 (2.71%)		
occurrences (all)	6	8		

respiratory tract congestion			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
rhinitis allergic			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	3 / 265 (1.13%)	3 / 258 (1.16%)	
occurrences (all)	3	3	
sinus congestion			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
tracheal inflammation			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
upper respiratory tract congestion			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
upper respiratory tract inflammation			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
upper-airway cough syndrome			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	0 / 258 (0.00%)	
occurrences (all)	3	0	
wheezing			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	1 / 258 (0.39%)	
occurrences (all)	2	1	
Psychiatric disorders			

anxiety			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	8 / 265 (3.02%)	6 / 258 (2.33%)	
occurrences (all)	10	6	
confusional state			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	3 / 265 (1.13%)	1 / 258 (0.39%)	
occurrences (all)	4	1	
depressive symptom			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
depression			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	4 / 265 (1.51%)	3 / 258 (1.16%)	
occurrences (all)	4	3	
delirium			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences (all)	1	1	
disorientation			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
emotional distress			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
euphoric mood			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
insomnia			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	10 / 265 (3.77%)	23 / 258 (8.91%)	
occurrences (all)	11	25	
irritability			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	2 / 258 (0.78%)	
occurrences (all)	0	2	
restlessness			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
sleep disorder			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences (all)	1	1	
sleep talking			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
Product issues			
device occlusion			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
Hepatobiliary disorders			
cholelithiasis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
hepatic failure			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
hepatic function abnormal			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
hepatic pain			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
jaundice			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences (all)	1	1	
Investigations			
activated partial thromboplastin time prolonged			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
alanine aminotransferase increased			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	8 / 265 (3.02%)	9 / 258 (3.49%)	
occurrences (all)	8	9	
aspartate aminotransferase increased			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	9 / 265 (3.40%)	11 / 258 (4.26%)	
occurrences (all)	9	12	
blood alkaline phosphatase			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
blood alkaline phosphatase increased			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	11 / 265 (4.15%)	4 / 258 (1.55%)	
occurrences (all)	14	4	
blood bilirubin increased			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	1 / 265 (0.38%)	2 / 258 (0.78%)		
occurrences (all)	1	6		
blood calcium decreased alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)		
occurrences (all)	1	0		
blood creatine increased alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)		
occurrences (all)	1	0		
blood creatinine increased alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	21 / 265 (7.92%)	8 / 258 (3.10%)		
occurrences (all)	31	8		
blood lactate dehydrogenase increased alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	0 / 265 (0.00%)	2 / 258 (0.78%)		
occurrences (all)	0	2		
blood pressure decreased alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)		
occurrences (all)	1	0		
blood pressure increased alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	3 / 265 (1.13%)	3 / 258 (1.16%)		
occurrences (all)	7	9		
blood thyroid stimulating hormone increased alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)		
occurrences (all)	1	0		
blood urea increased alternative dictionary used: MedDRA 26.0				

subjects affected / exposed	2 / 265 (0.75%)	0 / 258 (0.00%)	
occurrences (all)	2	0	
blood uric acid increased			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
body temperature increased			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
carbon dioxide decreased			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	2 / 258 (0.78%)	
occurrences (all)	0	3	
clostridium test positive			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
creatinine renal clearance decreased			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	2	0	
electrocardiogram st segment depression			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
gamma-glutamyltransferase increased			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	10 / 265 (3.77%)	1 / 258 (0.39%)	
occurrences (all)	13	1	
heart rate increased			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
international normalised ratio increased			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences (all)	1	1	
lymphocyte count decreased			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	8 / 265 (3.02%)	5 / 258 (1.94%)	
occurrences (all)	26	15	
lymphocyte count increased			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	2	0	
neutrophil count decreased			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	29 / 265 (10.94%)	29 / 258 (11.24%)	
occurrences (all)	71	93	
neutrophil count increased			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
platelet count decreased			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	6 / 265 (2.26%)	21 / 258 (8.14%)	
occurrences (all)	9	56	
platelet count increased			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
protein total increased			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	

protein urine			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
protein urine present			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	4	
prothrombin time prolonged			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
total lung capacity decreased			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
troponin t increased			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
weight increased			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	3 / 265 (1.13%)	1 / 258 (0.39%)	
occurrences (all)	3	1	
weight decreased			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	21 / 265 (7.92%)	23 / 258 (8.91%)	
occurrences (all)	28	26	
white blood cells urine positive			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
white blood cells urine			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
white blood cell count increased			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
white blood cell count decreased			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	21 / 265 (7.92%)	19 / 258 (7.36%)	
occurrences (all)	54	77	
Injury, poisoning and procedural complications			
contusion			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	2 / 258 (0.78%)	
occurrences (all)	1	2	
eschar			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
fall			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	3 / 258 (1.16%)	
occurrences (all)	1	3	
fracture			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
head injury			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
infusion related reaction			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	6 / 265 (2.26%)	7 / 258 (2.71%)		
occurrences (all)	6	9		
jaw fracture				
alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)		
occurrences (all)	1	0		
joint injury				
alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)		
occurrences (all)	0	1		
limb injury				
alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)		
occurrences (all)	0	1		
nail injury				
alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)		
occurrences (all)	0	1		
pelvic fracture				
alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)		
occurrences (all)	0	1		
penis injury				
alternative dictionary used: MedDRA 26.0				
subjects affected / exposed[14]	1 / 214 (0.47%)	0 / 258 (0.00%)		
occurrences (all)	1	0		
periorbital haematoma				
alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)		
occurrences (all)	0	1		
post procedural haemorrhage				
alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	0 / 265 (0.00%)	3 / 258 (1.16%)		
occurrences (all)	0	3		

procedural pain			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences (all)	1	1	
procedural nausea			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
rib fracture			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
skin abrasion			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	1 / 258 (0.39%)	
occurrences (all)	2	1	
spinal fracture			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
thermal burn			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
stoma site pain			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
urinary tract stoma complication			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
vascular access complication			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
wound complication			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
wound			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
Congenital, familial and genetic disorders			
haemophilia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
Cardiac disorders			
angina pectoris			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
atrial fibrillation			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences (all)	1	1	
atrioventricular block first degree			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	0 / 258 (0.00%)	
occurrences (all)	2	0	
arrhythmia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
cardiac failure			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	0 / 265 (0.00%)	2 / 258 (0.78%)	
occurrences (all)	0	2	
cardiovascular disorder			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
bradycardia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
left ventricular dysfunction			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
palpitations			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	2 / 258 (0.78%)	
occurrences (all)	2	3	
pericardial effusion			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
sinus bradycardia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences (all)	1	1	
sinus tachycardia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	4 / 265 (1.51%)	0 / 258 (0.00%)	
occurrences (all)	4	0	
right atrial enlargement			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	

tachyarrhythmia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
tachycardia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	3 / 258 (1.16%)	
occurrences (all)	2	3	
Nervous system disorders			
ageusia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	3 / 265 (1.13%)	0 / 258 (0.00%)	
occurrences (all)	3	0	
amnesia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences (all)	1	1	
ataxia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
clonus			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	2	0	
depressed level of consciousness			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	3	0	
drooling			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
dizziness postural			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
dizziness			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	9 / 265 (3.40%)	7 / 258 (2.71%)	
occurrences (all)	9	8	
disturbance in attention			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	2 / 258 (0.78%)	
occurrences (all)	0	2	
dysgeusia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	18 / 265 (6.79%)	28 / 258 (10.85%)	
occurrences (all)	19	41	
dysarthria			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	2	
dysaesthesia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
head titubation			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	2	0	
headache			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	14 / 265 (5.28%)	19 / 258 (7.36%)	
occurrences (all)	15	27	
hypoaesthesia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	3 / 265 (1.13%)	2 / 258 (0.78%)	
occurrences (all)	3	2	

hypotonia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
lethargy			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	3 / 258 (1.16%)	
occurrences (all)	1	3	
memory impairment			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	2 / 258 (0.78%)	
occurrences (all)	1	2	
nervous system disorder			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
neuralgia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
neuropathy peripheral			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	13 / 265 (4.91%)	7 / 258 (2.71%)	
occurrences (all)	16	9	
neurotoxicity			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	3 / 258 (1.16%)	
occurrences (all)	2	3	
paraesthesia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	14 / 265 (5.28%)	5 / 258 (1.94%)	
occurrences (all)	15	7	
peripheral sensory neuropathy			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	22 / 265 (8.30%)	18 / 258 (6.98%)	
occurrences (all)	31	23	
peroneal nerve palsy			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
polyneuropathy			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
peripheral motor neuropathy			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	1 / 258 (0.39%)	
occurrences (all)	2	1	
presyncope			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
radiculopathy			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
sciatica			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences (all)	1	1	
syncope			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	0 / 258 (0.00%)	
occurrences (all)	2	0	
taste disorder			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	2 / 258 (0.78%)	
occurrences (all)	1	2	

somnolence			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	2 / 258 (0.78%)	
occurrences (all)	1	2	
tremor			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	3 / 265 (1.13%)	2 / 258 (0.78%)	
occurrences (all)	4	3	
Blood and lymphatic system disorders			
anaemia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	76 / 265 (28.68%)	50 / 258 (19.38%)	
occurrences (all)	140	87	
blood loss anaemia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
febrile neutropenia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	5 / 265 (1.89%)	9 / 258 (3.49%)	
occurrences (all)	5	9	
leukocytosis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	3 / 265 (1.13%)	1 / 258 (0.39%)	
occurrences (all)	3	1	
leukopenia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	5 / 265 (1.89%)	8 / 258 (3.10%)	
occurrences (all)	9	25	
lymph node pain			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
lymphopenia			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	2 / 265 (0.75%)	2 / 258 (0.78%)	
occurrences (all)	2	7	
neutropenia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	14 / 265 (5.28%)	18 / 258 (6.98%)	
occurrences (all)	14	36	
thrombocytopenia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	3 / 265 (1.13%)	6 / 258 (2.33%)	
occurrences (all)	3	13	
thrombocytosis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
Ear and labyrinth disorders			
ear discomfort			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	0 / 258 (0.00%)	
occurrences (all)	2	0	
ear canal stenosis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
hypoacusis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	2	0	
middle ear inflammation			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
otorrhoea			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
tinnitus			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences (all)	1	1	
vestibular disorder			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
vertigo			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	3 / 265 (1.13%)	0 / 258 (0.00%)	
occurrences (all)	4	0	
Eye disorders			
dry eye			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	3 / 258 (1.16%)	
occurrences (all)	2	3	
eczema eyelids			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
eye discharge			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
eye disorder			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
eye pain			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	0 / 265 (0.00%)	2 / 258 (0.78%)	
occurrences (all)	0	4	
eye pruritus			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences (all)	1	1	
eyelid function disorder			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
eyelid oedema			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
eyelid ptosis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
glaucoma			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
lacrimation increased			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	12 / 265 (4.53%)	24 / 258 (9.30%)	
occurrences (all)	12	28	
ocular discomfort			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
photopsia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	

retinal vascular disorder			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	2	0	
vitreous haemorrhage			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
vitreous detachment			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
visual impairment			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
vision blurred			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	3 / 258 (1.16%)	
occurrences (all)	1	3	
Gastrointestinal disorders			
abdominal discomfort			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	2 / 258 (0.78%)	
occurrences (all)	0	2	
abdominal distension			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	5 / 265 (1.89%)	7 / 258 (2.71%)	
occurrences (all)	5	7	
abdominal wall disorder			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	2	0	
abdominal pain lower			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences (all)	1	1	
abdominal pain upper			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	10 / 265 (3.77%)	12 / 258 (4.65%)	
occurrences (all)	10	15	
abdominal pain			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	17 / 265 (6.42%)	20 / 258 (7.75%)	
occurrences (all)	22	26	
anal fistula			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
anal haemorrhage			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
anal incontinence			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
anal inflammation			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences (all)	1	1	
angular cheilitis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
ascites			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	7 / 258 (2.71%)	
occurrences (all)	1	8	

cheilitis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
colitis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
constipation			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	45 / 265 (16.98%)	35 / 258 (13.57%)	
occurrences (all)	58	46	
diarrhoea			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	56 / 265 (21.13%)	81 / 258 (31.40%)	
occurrences (all)	81	131	
dysphagia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	6 / 258 (2.33%)	
occurrences (all)	2	6	
dyspepsia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	7 / 265 (2.64%)	9 / 258 (3.49%)	
occurrences (all)	7	10	
dyschezia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
dry mouth			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	5 / 265 (1.89%)	11 / 258 (4.26%)	
occurrences (all)	5	13	
ectopic gastric mucosa			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
eructation			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
epigastric discomfort			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
enterocolitis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
flatulence			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences (all)	1	1	
faeces discoloured			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
gastrointestinal obstruction			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
gastrointestinal motility disorder			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
gastritis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	

gastric polyps			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
food poisoning			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
gastrooesophageal reflux disease			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	4 / 265 (1.51%)	3 / 258 (1.16%)	
occurrences (all)	4	8	
gingival atrophy			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
gingival bleeding			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	3 / 258 (1.16%)	
occurrences (all)	0	3	
haematochezia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	3 / 258 (1.16%)	
occurrences (all)	2	3	
glossitis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
gingival pain			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	2	
hiatus hernia			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
hyperchlorhydria			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
haemorrhoidal haemorrhage			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
haemorrhoids			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	8 / 258 (3.10%)	
occurrences (all)	2	9	
ileus			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	2 / 258 (0.78%)	
occurrences (all)	1	2	
intestinal haemorrhage			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
intra-abdominal haematoma			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
large intestinal haemorrhage			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
lip blister			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	

mouth ulceration			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences (all)	1	1	
melaena			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences (all)	2	1	
lip dry			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
mucous stools			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
odynophagia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	0 / 258 (0.00%)	
occurrences (all)	2	0	
nausea			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	55 / 265 (20.75%)	71 / 258 (27.52%)	
occurrences (all)	82	102	
obstruction gastric			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	5	
oral disorder			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
oral hyperaesthesia			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
oral pain			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	1 / 258 (0.39%)	
occurrences (all)	2	1	
periodontal disease			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	1 / 258 (0.39%)	
occurrences (all)	2	2	
proctalgia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	2 / 258 (0.78%)	
occurrences (all)	1	2	
proctitis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
rectal haemorrhage			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	3 / 265 (1.13%)	1 / 258 (0.39%)	
occurrences (all)	3	1	
rectal prolapse			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
rectal tenesmus			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	2 / 258 (0.78%)	
occurrences (all)	1	2	
stomatitis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	30 / 265 (11.32%)	66 / 258 (25.58%)	
occurrences (all)	36	117	

toothache			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	4 / 265 (1.51%)	1 / 258 (0.39%)	
occurrences (all)	4	1	
upper gastrointestinal haemorrhage			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
vomiting			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	40 / 265 (15.09%)	41 / 258 (15.89%)	
occurrences (all)	56	62	
Skin and subcutaneous tissue disorders			
acne			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
alopecia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	94 / 265 (35.47%)	66 / 258 (25.58%)	
occurrences (all)	115	79	
dermatitis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
decubitus ulcer			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
dermatitis acneiform			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
dry skin			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	6 / 265 (2.26%)	11 / 258 (4.26%)	
occurrences (all)	6	12	
drug eruption			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
eczema			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	2 / 258 (0.78%)	
occurrences (all)	0	4	
epidermolysis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
erythema			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	3 / 265 (1.13%)	6 / 258 (2.33%)	
occurrences (all)	3	7	
erythema multiforme			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	3 / 265 (1.13%)	0 / 258 (0.00%)	
occurrences (all)	3	0	
hyperhidrosis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	2 / 258 (0.78%)	
occurrences (all)	2	2	
nail bed disorder			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
nail bed inflammation			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	

nail discolouration			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	15 / 265 (5.66%)	7 / 258 (2.71%)	
occurrences (all)	15	7	
nail disorder			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	3 / 265 (1.13%)	3 / 258 (1.16%)	
occurrences (all)	3	3	
nail dystrophy			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
nail toxicity			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	2 / 258 (0.78%)	
occurrences (all)	1	4	
night sweats			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	2 / 258 (0.78%)	
occurrences (all)	2	2	
nail ridging			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	3 / 265 (1.13%)	6 / 258 (2.33%)	
occurrences (all)	3	7	
onychalgia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	5	
onycholysis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	5 / 258 (1.94%)	
occurrences (all)	3	7	
onychomadesis			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	5 / 265 (1.89%)	8 / 258 (3.10%)	
occurrences (all)	5	10	
onychoclasis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
pain of skin			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	3 / 258 (1.16%)	
occurrences (all)	0	3	
palmar-plantar erythrodysaesthesia syndrome			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	6 / 265 (2.26%)	19 / 258 (7.36%)	
occurrences (all)	15	28	
photosensitivity reaction			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	2	
pruritus			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	12 / 265 (4.53%)	10 / 258 (3.88%)	
occurrences (all)	17	11	
rash			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	15 / 265 (5.66%)	11 / 258 (4.26%)	
occurrences (all)	18	14	
rash erythematous			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
rash maculo-papular			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	5 / 265 (1.89%)	0 / 258 (0.00%)	
occurrences (all)	5	0	

skin burning sensation			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
skin discolouration			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
skin disorder			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	2	
skin exfoliation			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
skin fissures			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
skin hyperpigmentation			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	2 / 258 (0.78%)	
occurrences (all)	2	2	
skin lesion			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
skin ulcer			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	2 / 258 (0.78%)	
occurrences (all)	0	3	
urticaria			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	4 / 265 (1.51%)	5 / 258 (1.94%)	
occurrences (all)	4	5	
xeroderma			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
Renal and urinary disorders			
acute kidney injury			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	5 / 258 (1.94%)	
occurrences (all)	0	5	
anuria			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
bladder pain			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences (all)	1	1	
chromaturia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences (all)	1	1	
chronic kidney disease			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
cystitis noninfective			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
cystitis interstitial			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)		
occurrences (all)	0	1		
dysuria				
alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	4 / 265 (1.51%)	3 / 258 (1.16%)		
occurrences (all)	4	3		
haematuria				
alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	19 / 265 (7.17%)	30 / 258 (11.63%)		
occurrences (all)	20	48		
hydronephrosis				
alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)		
occurrences (all)	0	1		
hydroureter				
alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)		
occurrences (all)	0	1		
micturition urgency				
alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	0 / 265 (0.00%)	2 / 258 (0.78%)		
occurrences (all)	0	2		
nocturia				
alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)		
occurrences (all)	0	1		
pollakiuria				
alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	4 / 265 (1.51%)	3 / 258 (1.16%)		
occurrences (all)	4	3		
polyuria				
alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)		
occurrences (all)	0	1		

proteinuria			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	16 / 265 (6.04%)	33 / 258 (12.79%)	
occurrences (all)	28	60	
renal failure			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	1 / 258 (0.39%)	
occurrences (all)	2	1	
renal impairment			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	2 / 258 (0.78%)	
occurrences (all)	1	2	
renal pain			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences (all)	1	1	
urinary hesitation			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
urethral haemorrhage			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
urinary fistula			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
urinary tract pain			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	0 / 258 (0.00%)	
occurrences (all)	2	0	
urinary tract obstruction			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	1 / 265 (0.38%)	2 / 258 (0.78%)	
occurrences (all)	1	2	
urinary retention			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	5 / 265 (1.89%)	1 / 258 (0.39%)	
occurrences (all)	6	1	
urinary incontinence			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	6 / 265 (2.26%)	1 / 258 (0.39%)	
occurrences (all)	6	1	
urine odour abnormal			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	1 / 258 (0.39%)	
occurrences (all)	2	1	
Endocrine disorders			
adrenal insufficiency			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
hypothyroidism			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	2 / 258 (0.78%)	
occurrences (all)	1	3	
Musculoskeletal and connective tissue disorders			
arthralgia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	26 / 265 (9.81%)	30 / 258 (11.63%)	
occurrences (all)	34	39	
arthritis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
back pain			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	21 / 265 (7.92%)	29 / 258 (11.24%)	
occurrences (all)	26	36	
bone pain			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	17 / 265 (6.42%)	15 / 258 (5.81%)	
occurrences (all)	19	15	
flank pain			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	5 / 265 (1.89%)	3 / 258 (1.16%)	
occurrences (all)	6	3	
groin pain			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	7 / 265 (2.64%)	4 / 258 (1.55%)	
occurrences (all)	7	6	
intervertebral disc disorder			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
intervertebral disc protrusion			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
inguinal mass			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
joint effusion			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
joint swelling			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	

limb discomfort			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
muscle fatigue			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
muscle spasms			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	4 / 265 (1.51%)	2 / 258 (0.78%)	
occurrences (all)	4	4	
muscle twitching			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
muscular weakness			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	6 / 265 (2.26%)	5 / 258 (1.94%)	
occurrences (all)	7	6	
musculoskeletal chest pain			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	3 / 265 (1.13%)	4 / 258 (1.55%)	
occurrences (all)	3	4	
musculoskeletal pain			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	4 / 265 (1.51%)	1 / 258 (0.39%)	
occurrences (all)	4	1	
myalgia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	23 / 265 (8.68%)	24 / 258 (9.30%)	
occurrences (all)	30	39	
myofascitis			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
neck mass			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
neck pain			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	5 / 265 (1.89%)	3 / 258 (1.16%)	
occurrences (all)	7	3	
osteoarthritis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
osteonecrosis of jaw			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
pain in extremity			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	16 / 265 (6.04%)	12 / 258 (4.65%)	
occurrences (all)	22	15	
pain in jaw			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
polymyalgia rheumatica			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
pubic pain			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	

sacral pain			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences (all)	1	1	
spinal pain			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
Infections and infestations			
abscess intestinal			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
anal abscess			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
bacteraemia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
bacteriuria			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
covid-19			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
cellulitis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	2 / 258 (0.78%)	
occurrences (all)	2	3	
breast cellulitis			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)		
occurrences (all)	1	0		
bronchitis				
alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	3 / 265 (1.13%)	4 / 258 (1.55%)		
occurrences (all)	3	4		
conjunctivitis				
alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	1 / 265 (0.38%)	5 / 258 (1.94%)		
occurrences (all)	1	6		
cystitis				
alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	1 / 265 (0.38%)	2 / 258 (0.78%)		
occurrences (all)	1	2		
device related infection				
alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	0 / 265 (0.00%)	2 / 258 (0.78%)		
occurrences (all)	0	2		
dacryocystitis				
alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)		
occurrences (all)	0	2		
enterovirus infection				
alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)		
occurrences (all)	1	0		
eye infection				
alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	2 / 265 (0.75%)	0 / 258 (0.00%)		
occurrences (all)	2	0		
gastroenteritis				
alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)		
occurrences (all)	1	0		

furuncle			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	2 / 258 (0.78%)	
occurrences (all)	0	2	
fungal infection			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
gingivitis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	4 / 258 (1.55%)	
occurrences (all)	2	4	
helicobacter infection			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
herpes dermatitis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
herpes virus infection			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	2	0	
herpes zoster			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	2 / 258 (0.78%)	
occurrences (all)	1	2	
influenza			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	3 / 258 (1.16%)	
occurrences (all)	1	3	
infective glossitis			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)		
occurrences (all)	0	1		
infection				
alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)		
occurrences (all)	0	1		
kidney infection				
alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)		
occurrences (all)	1	0		
lower respiratory tract infection				
alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)		
occurrences (all)	0	1		
nail bed infection				
alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)		
occurrences (all)	0	3		
nail infection				
alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	1 / 265 (0.38%)	5 / 258 (1.94%)		
occurrences (all)	1	7		
mucosal infection				
alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)		
occurrences (all)	1	1		
nasopharyngitis				
alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	3 / 265 (1.13%)	5 / 258 (1.94%)		
occurrences (all)	3	5		
onychomycosis				
alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)		
occurrences (all)	2	0		

oral candidiasis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	3 / 265 (1.13%)	5 / 258 (1.94%)	
occurrences (all)	3	5	
oral fungal infection			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
oral herpes			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
paronychia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	2 / 258 (0.78%)	
occurrences (all)	0	3	
parotitis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
perineal abscess			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	2	0	
perineal infection			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	2	
postoperative wound infection			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
peritonitis bacterial			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)		
occurrences (all)	0	1		
pharyngitis				
alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)		
occurrences (all)	1	2		
pneumonia				
alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	3 / 265 (1.13%)	1 / 258 (0.39%)		
occurrences (all)	5	1		
post procedural infection				
alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)		
occurrences (all)	0	1		
pyelonephritis				
alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)		
occurrences (all)	0	2		
pyelonephritis acute				
alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)		
occurrences (all)	0	1		
respiratory tract infection				
alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)		
occurrences (all)	0	1		
respiratory tract infection viral				
alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)		
occurrences (all)	0	1		
rhinitis				
alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	1 / 265 (0.38%)	3 / 258 (1.16%)		
occurrences (all)	1	5		

sepsis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
sinusitis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	1 / 258 (0.39%)	
occurrences (all)	2	1	
skin infection			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences (all)	1	1	
spinal cord infection			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
tooth infection			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	3 / 258 (1.16%)	
occurrences (all)	0	3	
tooth abscess			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	2 / 258 (0.78%)	
occurrences (all)	0	2	
tonsillitis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
tinea pedis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
tracheitis			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
upper respiratory tract infection			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	9 / 265 (3.40%)	5 / 258 (1.94%)	
occurrences (all)	9	5	
urethritis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
urinary tract infection			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	34 / 265 (12.83%)	31 / 258 (12.02%)	
occurrences (all)	39	38	
viral upper respiratory tract infection			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
viral infection			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
Metabolism and nutrition disorders			
acidosis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
cachexia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
dehydration			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	5 / 265 (1.89%)	8 / 258 (3.10%)	
occurrences (all)	5	8	
decreased appetite			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	64 / 265 (24.15%)	82 / 258 (31.78%)	
occurrences (all)	82	128	
fluid retention			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
gout			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences (all)	1	1	
hypercalcaemia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	12 / 265 (4.53%)	6 / 258 (2.33%)	
occurrences (all)	15	11	
hyperglycaemia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	13 / 265 (4.91%)	8 / 258 (3.10%)	
occurrences (all)	15	12	
hyperkalaemia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	7 / 265 (2.64%)	12 / 258 (4.65%)	
occurrences (all)	12	26	
hypophosphataemia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	7 / 265 (2.64%)	6 / 258 (2.33%)	
occurrences (all)	8	10	
hypophagia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	

hyponatraemia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	10 / 265 (3.77%)	7 / 258 (2.71%)	
occurrences (all)	11	10	
hypomagnesaemia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	5 / 265 (1.89%)	4 / 258 (1.55%)	
occurrences (all)	7	4	
hypokalaemia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	5 / 265 (1.89%)	3 / 258 (1.16%)	
occurrences (all)	7	3	
hypocalcaemia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	4 / 265 (1.51%)	2 / 258 (0.78%)	
occurrences (all)	6	2	
hypoalbuminaemia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	26 / 265 (9.81%)	17 / 258 (6.59%)	
occurrences (all)	32	25	
hyperuricaemia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	15 / 265 (5.66%)	10 / 258 (3.88%)	
occurrences (all)	17	11	
hypernatraemia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
hypermagnesaemia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences (all)	2	1	
vitamin d deficiency			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed occurrences (all)	1 / 265 (0.38%) 1	1 / 258 (0.39%) 1	

Notes:

[2] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.

[3] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.

[4] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.

[5] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.

[6] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.

[7] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.

[8] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.

[9] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.

[10] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.

[11] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.

[12] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.

[13] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.

[14] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported